Gene Cream Could Cure Rare Skin Disease With One Treatment

For people born with autosomal recessive congenital ichthyosis, every day means living with extremely dry, scaly skin that cracks, burns, and invites constant infection. Now, a team of scientists has created something that seemed impossible: a cream that could fix the genetic cause of their suffering.

Researchers at the University of British Columbia, working with colleagues in Germany, developed the first gene therapy that can be applied directly to skin like a topical treatment. Their breakthrough, published in Cell Stem Cell, targets the root cause of genetic skin diseases rather than just managing symptoms.

The treatment combines two existing technologies in a completely new way. First, doctors use a painless medical laser to create microscopic openings in the skin's outer layer. Then they apply lipid nanoparticles, the same "fat bubbles" that helped deliver COVID vaccines, loaded with CRISPR gene-editing tools that slip through those tiny openings to reach stem cells below the surface.

Once inside, the gene editor corrects the faulty DNA. In lab tests using living human skin models, the treatment restored up to 30 percent of normal skin function for patients with ichthyosis, a threshold researchers believe could return skin to near-normal health.

Dr. Sarah Hedtrich, the study's senior author and associate professor at UBC's school of biomedical engineering, emphasizes what makes this approach revolutionary. The treatment stays localized in the skin with no evidence of affecting other parts of the body, addressing one of the biggest safety concerns with gene therapy.

Autosomal recessive congenital ichthyosis affects roughly one in 100,000 people worldwide. Babies are born with the condition, and it causes lifelong physical pain along with the emotional toll of visible symptoms that many find isolating and stigmatizing.

The Ripple Effect

While ichthyosis is rare, this platform technology could transform treatment for far more common conditions. The same approach could be adapted for epidermolysis bullosa, where skin blisters at the slightest touch, earning it the heartbreaking nickname "butterfly skin."

The researchers believe their method could eventually treat eczema and psoriasis, conditions affecting tens of millions of people globally. Each of these diseases could potentially be addressed by swapping in different gene-editing instructions while keeping the same delivery system.

The UBC team has already begun working with regulatory authorities to design the safety and efficacy studies needed before human clinical trials. Vancouver-based biotech company NanoVation Therapeutics, a UBC spinoff, is collaborating to move the treatment from lab to clinic.

For patients who currently face a lifetime of managing incurable symptoms, this research offers something they've never had before: the possibility of a one-time treatment that addresses the underlying cause of their condition, not just the pain it creates.